B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

P/FCFE
Price to FCFE

27
Current
4.3
Median
25.2
Industry
Higher than median
Higher than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
27
=
Market Cap
469.5B KRW
/
FCFE
17.4B KRW
All Countries
Close
Market Cap P/FCFE
KR
BioNote Inc
KRX:377740
469.5B KRW 27
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 227 395.3
US
Abbvie Inc
NYSE:ABBV
312.7B USD 12.5
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD -87.8
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 11.2
US
Epizyme Inc
F:EPE
94.1B EUR -425.2
AU
CSL Ltd
ASX:CSL
133.6B AUD 79
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 24.5
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
34.8B EUR -109.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More